Search 

Based on the corporate philosophy of "Takeda-ism" (Integrity: Fairness, Honesty and Perseverance) developed over its long corporate history of more than 230 years, Takeda conducts activities according to the corporate mission to “strive towards better health for people worldwide through leading innovation in medicine.”

Tanner-Ibbotson recognizes the importance of innovation and technological advances in Public Health.  Companies that research and manufacture medical devices, diagnostics, therapeutics and pharmaceuticals are exposed to risk at each level of development. An unexpected event can prevent the next big advancement from ever making it to the marketplace.  Life Science companies require a specialized comprehensive insurance and risk management program.  
 
New York State is recognized as one of the epicenters of Innovation in Life Sciences in the United States.  Tanner-Ibbotson has partnered with PRS Brokers to meet the unique and specific needs of Life Science Companies.  The partnership brings together close to 20 years experience in providing insurance and risk management solutions to the Life Science sector.
 
Expert knowledge of this industry enables us to tailor a program that can include:

• Property
• General Liability
• Auto Liability
• Product Liability
• Professional Liability
• Clinical Trials- US and Worldwide
• Management Liability
• Workers Compensation
• Product Recall
• Intellectual Property
• Transit/Ocean Marine

We serve Life Science companies in all stages from Research & Development to clinical trials to commercialization.
The industry includes the following:

• Medical Device Manufacturers & Distributors
• Pharmaceutical Manufacturers & Distributors
• Nutraceuticals/Supplements Manufacturers & Distributors
• Biotechnology Companies
• Medical Software Developers
• Nanotechnology Companies
• Contract Drug or Device Manufacturers
• Contract Research Organizations
• Site Management Organizations

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. 

TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! 

Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: 
- A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; 
- An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; 
- An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. 

We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.

The New York Stem Cell Foundation (NYSCF) is a non-profit organization whose mission is to accelerate stem cell research to cure the major diseases of our time. Our programs are focused in three areas: 

• Directing critical, advanced stem cell research in its own laboratory and also supports advanced work in other leading institutions. 

• Developing the next generation of top stem cell scientists by training and supporting an elite group of post-doctoral research fellows. 

• Convening the preeminent annual translation stem cell research conference and an on-going series of programs for scientists, policymakers and the public.

Medical Research, Events, Research Funding

Rare Genomics Institute empowers patient communities to accelerate research by helping fund and create personalized research projects based on individuals with rare diseases. Their first initiative is to sequence the genomes of these patients. To do this, they provide three innovative services. First, a micro-funding website: an online fundraising platform and social network that helps patient communities raise funds. Second, a researcher network: access to top genomics researchers who are willing to sequence and analyze these patients. Third, a clinical network: connecting patients with clinicians and genetic counselors who will help interpret and translate the individualized research findings.

Genomics, Rare Diseases, Next-Generation Sequencing, Crowdfunding